These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 37267579)

  • 1. Early Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer.
    Wala J; Nguyen P; Pomerantz M
    J Clin Oncol; 2023 Jul; 41(20):3584-3590. PubMed ID: 37267579
    [No Abstract]   [Full Text] [Related]  

  • 2. Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer: Updated Network Meta-analysis Stratified by Disease Volume.
    Hoeh B; Garcia CC; Wenzel M; Tian Z; Tilki D; Steuber T; Karakiewicz PI; Chun FKH; Mandel P
    Eur Urol Focus; 2023 Sep; 9(5):838-842. PubMed ID: 37055323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients: A Systematic Review and Network Meta-analysis.
    Mandel P; Hoeh B; Wenzel M; Preisser F; Tian Z; Tilki D; Steuber T; Karakiewicz PI; Chun FKH
    Eur Urol Focus; 2023 Jan; 9(1):96-105. PubMed ID: 36058809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Androgen deprivation therapy plus chemotherapy ± androgen receptor-targeting agents for metastatic hormone-sensitive prostate cancer].
    Wenzel M; Hoeh B; Chun FKH; Mandel P
    Urologie; 2023 Apr; 62(4):360-368. PubMed ID: 36763112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Addition of New Androgen Receptor Pathway Inhibitors to Docetaxel and Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review and Metanalysis.
    Fiorica F; Buttigliero C; Grigolato D; Muraro M; Turco F; Munoz F; Tucci M
    Curr Oncol; 2022 Dec; 29(12):9511-9524. PubMed ID: 36547161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen Receptor Signaling Inhibitors in Addition to Docetaxel with Androgen Deprivation Therapy for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis.
    Yanagisawa T; Rajwa P; Thibault C; Gandaglia G; Mori K; Kawada T; Fukuokaya W; Shim SR; Mostafaei H; Motlagh RS; Quhal F; Laukhtina E; Pallauf M; Pradere B; Kimura T; Egawa S; Shariat SF
    Eur Urol; 2022 Dec; 82(6):584-598. PubMed ID: 35995644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of disease volume on survival efficacy of triplet therapy for metastatic hormone-sensitive prostate cancer: a systematic review, meta-analysis, and network meta-analysis.
    Matsukawa A; Rajwa P; Kawada T; Bekku K; Laukhtina E; Klemm J; Pradere B; Mori K; Karakiewicz PI; Kimura T; Chlosta P; Shariat SF; Yanagisawa T
    Int J Clin Oncol; 2024 Jun; 29(6):716-725. PubMed ID: 38582807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Addition of Docetaxel to Androgen Receptor Axis-targeted Therapy and Androgen Deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer: A Network Meta-analysis.
    Roy S; Sayyid R; Saad F; Sun Y; Lajkosz K; Ong M; Klaassen Z; Malone S; Spratt DE; Wallis CJD; Morgan SC
    Eur Urol Oncol; 2022 Oct; 5(5):494-502. PubMed ID: 35811293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Addition of androgen receptor-targeted agents to androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis.
    Maiorano BA; De Giorgi U; Roviello G; Messina C; Altavilla A; Cattrini C; Mennitto A; Maiello E; Di Maio M
    ESMO Open; 2022 Oct; 7(5):100575. PubMed ID: 36152486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy and advanced androgen blockage, alone or combined, for metastatic hormone-sensitive prostate cancer a systematic review and meta-analysis.
    Fallara G; Robesti D; Nocera L; Raggi D; Marandino L; Belladelli F; Montorsi F; Malavaud B; Ploussard G; Necchi A; Martini A
    Cancer Treat Rev; 2022 Nov; 110():102441. PubMed ID: 35939976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer: a patient and caregiver perspective and plain language summary of the ARASENS trial.
    Smith MR; Hussain M; Saad F; Fizazi K; Sternberg CN; Crawford D; Manarite J; Muslin D; Farrington T; Tombal B
    Future Oncol; 2022 Jul; 18(21):2585-2597. PubMed ID: 35656777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Darolutamide: A Review in Metastatic Hormone-Sensitive Prostate Cancer.
    Lee A
    Target Oncol; 2023 Sep; 18(5):793-800. PubMed ID: 37542594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate Radiotherapy in Low-volume Metastatic Hormone-sensitive Prostate Cancer: A Network Meta-analysis.
    Roy S; Fervaha G; Spratt DE; Sun Y; Kishan AU; Loblaw A; Malone S; Ong M; Saad F; Wallis CJD; Morgan SC
    Eur Urol; 2024 Jul; 86(1):10-17. PubMed ID: 38570246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Darolutamide in Combination With Androgen-Deprivation Therapy and Docetaxel in Black Patients From the Randomized ARASENS Trial.
    Shore ND; Hussain M; Saad F; Fizazi K; Sternberg CN; Crawford D; Tombal B; Nordquist L; Cookson M; Verholen F; Jhaveri J; Srinivasan S; Smith MR
    Oncologist; 2024 Mar; 29(3):235-243. PubMed ID: 37812679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disease volume and risk subgroup analyses for darolutamide plus androgen-deprivation therapy and docetaxel in the phase III ARASENS: should triplet therapy become standard of care in certain metastatic hormone-sensitive prostate cancer patients?
    Hoeh B; Chun FKH; Mandel P
    Chin Clin Oncol; 2024 Feb; 13(1):14. PubMed ID: 37817509
    [No Abstract]   [Full Text] [Related]  

  • 16. Systemic therapies for high-volume metastatic hormone-sensitive prostate cancer: a network meta-analysis.
    Zhou Z; Liu S; Mei J; Liu T; Liu F; Zhang G
    Acta Oncol; 2023 Sep; 62(9):1083-1090. PubMed ID: 37548225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-World Evidence of Triplet Therapy in Metastatic Hormone-Sensitive Prostate Cancer: An Austrian Multicenter Study.
    Kafka M; Giannini G; Artamonova N; Neuwirt H; Ofner H; Kramer G; Bauernhofer T; Luger F; Höfner T; Loidl W; Griessner H; Lusuardi L; Bergmaier A; Berger A; Winder T; Weiss S; Bauinger S; Krause S; Drerup M; Heinrich E; Schneider M; Madersbacher S; Vallet S; Stoiber F; Laimer S; Hruby S; Schachtner G; Nagele U; Lenart S; Ponholzer A; Pfuner J; Wiesinger C; Kamhuber C; Müldür E; Bektic J; Horninger W; Heidegger I
    Clin Genitourin Cancer; 2024 Apr; 22(2):458-466.e1. PubMed ID: 38267304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SYSTEMIC TRIPLE THERAPY IN METASTATIC HORMONE SENSITIVE PROSTATE CANCER (MHSPC).
    Omrčen T
    Acta Clin Croat; 2022 Oct; 61(Suppl 3):81-85. PubMed ID: 36938560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world treatment of metastatic hormone-sensitive prostate cancer in the USA, Europe and Asia.
    Goebell PJ; Raina R; Chen S; Rege S; Shah R; Grossman JP; Waldeck AR
    Future Oncol; 2024 May; 20(14):903-918. PubMed ID: 38353055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Network meta-analysis of combination strategies in metastatic hormone-sensitive prostate cancer.
    Wang SS; Bian XJ; Wu JL; Wang BH; Zhang S; Ye DW
    Asian J Androl; 2024 Jul; 26(4):402-408. PubMed ID: 38624195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.